That's a pretty interesting abstract. Even though I didn't really understand exactly how Campath fit into the whole scheme of the clinical trial, the results seem very promising. I think it would be useful if ILXO put out a press release about this AML study to clarify the issue, and explain to investors how this study fits into the big picture.
To me, it will be interesting to see what kind of off-label usage Campath gets once it is approved for its first indication. If oncologists think that results are looking good in various trials, they may well be tempted to use Campath more widely. Obviously, this could have significant revenue implications. We shall see.
As for the general market stinkiness and ILXO's current price performance, I have no comment other than an occassional sigh or snort of derision. ILXO will go higher (I think). It's too good of a deal at the current price. Unfortunately, patience is not one of my strong points.